Product Description
Bepotastine ophthalmic is used to treat itching of the eyes caused by allergic conjunctivitis (a condition in which the eyes become itchy, swollen, red, and teary when they are exposed to certain substances in the air).
Mechanisms of Action: HRH1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | Canada | Ecuador | Egypt | India | Indonesia | Japan | Korea | Mexico | Philippines | Taiwan | United States | Uruguay
Approved Indications: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/05/2024 |
News Article |
Managed SIEM Services Market worth $16.0 billion by 2028 - Exclusive Report by MarketsandMarkets™ |
|
10/04/2023 |
News Article |
Allergic Rhinitis Drugs Market Key Strategies, Application, Growth, Trends and Opportunities 2030 |
|
11/04/2021 |
News Article |
Lamperd Less Lethal Receives First Purchase Order From Colorado Distributor Talion Defense Corp. to Supply Riot Control Products Marked "Made in the USA" |
|
08/12/2021 |
News Article |
Global Allergic Conjunctivitis Market to Surpass US$ 3,592.6 Million by 2028, Says Coherent Market Insights (CMI) |